REG - MyHealthChecked PLC - Issue of Equity

MyhealthcheckedAnnouncement

25/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220325:nRSY9873Fa&default-theme=true

RNS Number : 9873F  MyHealthChecked PLC  25 March 2022

MyHealthChecked plc

("MyHealthChecked" or "the Company")

 

Issue of Equity

Performance related deferred consideration to be satisfied in full

 

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company,
announces that a deferred consideration of £0.24m, payable in shares, has
been made in relation to the acquisition of The Genome Store Ltd ("The Genome
Store"), after all performance milestones were met.

 

The Genome Store, a provider of home-administered postal genomic test
services, was acquired by MyHealthChecked in November 2020, and the deferred
consideration was conditional upon the achievement of revenue targets along
with other operational criteria including new product development targets.

 

The deferred consideration will be satisfied by the issue of 24 million new
ordinary shares of 0.1p each ("New Ordinary Shares") in the capital of the
Company at an issue price of 1p per share.

 

Admission of the New Ordinary Shares to trading on AIM and Total Voting Rights

The New Ordinary Shares have been allotted and application will be made for
their admission to trading ("Admission") on the AIM Market of the London Stock
Exchange. Admission is expected to take place on or around 30 March 2022.

 

The New Ordinary Shares will, when issued, be credited as fully paid and will
rank equally in all respects with the existing Ordinary Shares, including the
right to receive any dividend or other distribution declared, made or paid
after Admission.

 

For the purposes of the Financial Conduct Authority's Disclosure and
Transparency Rules ("DTRs"), the issued ordinary share capital of the Company
following Admission will consist of 780,088,967 Ordinary Shares with voting
rights attached (one vote per Ordinary Share). There are no Ordinary Shares
held in treasury. This total voting rights figure may be used by shareholders
as the denominator for the calculations by which they will determine whether
they are required to notify their interests in, or a change to their interest
in, the Company under the DTRs.

 

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "We are
delighted with the strong performance that we've seen from The Genome Store
business since becoming part of MyHealthChecked at the end of 2020. The
acquisition was a natural fit and it gave us the expertise to meet the
opportunities that the COVID testing market provided. From this we have
established a trusted reputation with customers and built strong commercial
relationships with the UK's top pharmacy retailers. We now look forward to
further progressing an exciting pipeline of wider testing services for which
we will commence commercialisation this Spring."

 

For further information contact:

 

 MyHealthChecked plc                                                www.myhealthchecked.com (http://www.myhealthchecked.com)
 Penny McCormick, Chief Executive Officer                           via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                            Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Oberon Capital Ltd (Broker)                                        Tel: +44 (0)203 179 5344
 Mike Seabrook                                                      mikeseabrook@oberoninvestments.com (mailto:mikeseabrook@oberoninvestments.com)

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                   (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus                                                       Mob: +44(0)7980 541 893

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests,
now in development following the acquisition of The Genome Store in November
2020. The tests will be made available online, and would be viable for over
the counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFFFVFVSISFIF